Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) Innovative Solutions Opening (ISO)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Contract Value
Not provided
Codes & Classification
Solicitation Number
ARPA-H-SOL-26-142
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AN13
Additional Details
The Advanced Research Projects Agency for Health (ARPA-H), operating under the Department of Health and Human Services and the National Institutes of Health, has issued a solicitation for the Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) Innovative Solutions Opening (ISO), procurement identifier ARPA-H-SOL-26-142. This active opportunity seeks to catalyze the development of advanced agentic systems capable of delivering autonomous and semi-autonomous clinical care directly to patients with cardiovascular disease (CVD), representing a significant step forward in the integration of artificial intelligence into healthcare delivery.
The primary objective of the ADVOCATE program is to foster innovative research and development in biotechnology—specifically, the creation and validation of AI-driven solutions that can transform cardiovascular care management. The envisioned agentic system will leverage cutting-edge AI to support or automate clinical decision-making and patient management, with the ultimate goal of improving outcomes for individuals with CVD. The program is structured to support a range of technical areas (TAs), with clear delineations regarding eligibility and participation to ensure focused and non-overlapping efforts among proposers.
Key requirements and deliverables for this solicitation include:
- The design, development, and demonstration of reliable agentic care management systems (as outlined in Technical Area 1, TA1).
- Execution of scalability studies over a 15-month Phase 2 period, aimed at validating the system’s ability to operate effectively at scale.
- Adherence to rigorous scientific and technical merit criteria, as well as robust processes for the handling of sensitive information.
- Collaboration expectations among performers, with specific restrictions on team composition for certain technical areas (e.g., proposers for TA3 may not participate in TA1 or TA2 in any capacity).
- Full disclosure and management of potential organizational conflicts of interest (OCI) as part of the proposal process.
The solicitation has undergone multiple amendments to clarify and update requirements, including revisions to the table of contents, technical area descriptions, program structure and timeline, submission information, evaluation criteria, and performer collaboration expectations. Interested parties are encouraged to review all attached amendments and the full solicitation documentation for comprehensive details.
The procurement is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with a place of performance in Washington, District of Columbia. The Product Service Code is AN13, further indicating a focus on R&D in health-related biotechnology.
This opportunity is open to qualified organizations capable of advancing the state of the art in AI-enabled healthcare solutions, particularly those with expertise in biotechnology, artificial intelligence, and clinical care systems. The solicitation does not specify any set-aside requirements or special considerations beyond those outlined in the amendments and technical area restrictions.
The response deadline for this solicitation is April 1, 2026. Interested contractors should refer to the official notice and attachments on SAM.gov (Opportunity ID: 2a3d4bf519044e689f66a8ca36d992e2) for detailed instructions and contact information. While a primary contact is referenced, proposers are directed to consult the description section for further guidance.
In summary, the ADVOCATE ISO represents a significant federal investment in the future of AI-driven cardiovascular care, offering a unique opportunity for organizations at the forefront of biotechnology and digital health innovation to contribute to transformative healthcare solutions.
Documents7